Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

A team at Kobe University has created a game-changing resource for autism research: 63 mouse embryonic stem cell lines, each ...

Amid a challenging gene editing climate, partnerships between researchers, regulators, and industry remain crucial for ...

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

Japanese researchers have successfully eliminated the extra chromosome responsible for Down syndrome using CRISPR gene ...

For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...

Crispr Therapeutics' current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles. Click ...

Editas Medicine ( EDIT 12.04%) is a promising clinical-stage company that has captured Wall Street's attention at the ...

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an ...

A newly discovered bacterial defense protein named Cat1 reveals an extraordinary method of viral neutralization. All living ...